Clinical Trial

Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)

Study acronym: REFINE
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to assess whether treatment with rituximab in patients with MG will: * Allow faster and greater corticosteroid tapering * Reduce the frequency of exacerbations * Improve quality of life * Offer an acceptable safety and tolerability profile.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-05-11; most recent amendment 2025-07-30.
Trial Details
NCT Number NCT05868837
Lead Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions Myasthenia Gravis, Generalized
Enrollment 40 participants
Start Date 2022-02-28
Primary Completion 2025-07-31 (estimated)
Study Completion 2025-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-01